chloroquine and derivatives for COVID-19: living meta-analysis of clinical studies

Table Graph

chloroquine and derivatives - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	1.12 [0.99, 1.27]	< 1	33%	5 studies (4/1)	3.2 %	serious	not evaluable	low	crucial	-
deaths	0.83 [0.69, 1.00]	< 1	77%	41 studies (27/14)	97.5 %	moderate	low	moderate	crucial	-
deaths (time to event analysis only)	0.85 [0.64, 1.13]	< 1	92%	10 studies (3/7)	87.4 %	serious	low	low	crucial	-
clinical deterioration	1.05 [0.86, 1.27]	< 1	0%	7 studies (4/3)	32.0 %	serious	not evaluable	low	important	-
clinical improvement	1.02 [0.77, 1.35]	> 1	0%	2 studies (2/-)	54.9 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	0.95 [0.71, 1.25]	> 1	0%	3 studies (3/-)	35.1 %	low	not evaluable	high	important	-
clinical improvement (28-day)	0.97 [0.69, 1.37]	> 1	0%	1 study (1/-)	43.2 %	NA	not evaluable		important	-
clinical improvement (7-day)	1.16 [0.84, 1.61]	> 1	0%	1 study (1/-)	81.4 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	0.96 [0.81, 1.14]	> 1	0%	5 studies (4/1)	32.9 %	moderate	not evaluable	moderate	important	-
death or ventilation	1.12 [1.02, 1.22]	< 1	0%	6 studies (5/1)	0.6 %	moderate	not evaluable	moderate	important	-
hospital discharge	1.01 [0.82, 1.25]	> 1	0%	4 studies (3/1)	54.5 %	moderate	not evaluable	moderate	important	-
mechanical ventilation	0.98 [0.64, 1.49]	< 1	0%	1 study (-/1)	54.5 %	NA	not evaluable		important	-
mechanical ventilation (time to event analysis only)	1.43 [0.53, 3.82]	< 1	0%	1 study (-/1)	23.8 %	NA	not evaluable		important	-
radiologic improvement (7-day)	3.43 [1.10, 10.70]	> 1	0%	1 study (1/-)	98.3 %	NA	not evaluable		important	-
viral clearance	1.60 [0.63, 4.05]	> 1	76%	4 studies (3/1)	83.8 %	moderate	not evaluable	moderate	important	-
viral clearance (time to event analysis only)	1.00 [0.73, 1.38]	> 1	20%	3 studies (1/2)	51.1 %	serious	not evaluable	low	important	-
viral clearance by day 14	1.91 [0.42, 8.74]	> 1	82%	3 studies (1/2)	79.6 %	serious	not evaluable	low	important	-
ICU admission	1.19 [0.72, 1.96]	< 1	4%	2 studies (2/-)	24.6 %	some concern	not evaluable	moderate	non important	-
off oxygenation	0.98 [0.64, 1.51]	> 1	0%	1 study (1/-)	46.4 %	NA	not evaluable		non important	-
safety endpoints 00
cardiac arrest	1.91 [1.01, 3.62]	< 1	0%	2 studies (1/1)	2.3 %	serious	not evaluable	low	important	-
serious adverse events	1.26 [0.56, 2.84]	< 1	0%	1 study (1/-)	28.7 %	NA	not evaluable		important	-
abnormal ECG findings	1.50 [0.88, 2.57]	< 1	0%	1 study (-/1)	7.0 %	NA	not evaluable		non important	-
adverse events	1.60 [1.14, 2.25]	< 1	30%	8 studies (8/-)	0.4 %	some concern	not evaluable	moderate	non important	-
arrhythmia	1.05 [0.57, 1.94]	< 1	0%	1 study (-/1)	43.4 %	NA	not evaluable		non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

chloroquine and derivatives - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00